Founder mutations in BRCA1 and BRCA2 genes

被引:199
作者
Ferla, R.
Calo, V.
Cascio, S.
Rinaldi, G.
Badalamenti, G.
Carreca, I.
Surmacz, E.
Coliucci, G.
Bazan, V.
Russo, A.
机构
[1] Univ Palermo, Dept Surg & Oncol, Sect Med Oncol, Reg Reference Ctr Biomol Characterizat & Genet Sc, I-90127 Palermo, Italy
[2] Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA
[3] Natl Inst Oncol, Div Med Oncol, Bari, Italy
关键词
BRCA1; BRCA2; founder mutation;
D O I
10.1093/annonc/mdm234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to mutations in these tumor suppressor genes varies widely among populations. In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations are prevalent in restricted populations as consequence of a founder effect. The comparison of haplotypes between families with the same mutation can distinguish whether high-frequency alleles derive from an older or more recent single mutational event or whether they have arisen independently more than once. Here, we review some of the most well-known and significant examples of founder mutations in BRCA genes found in European and non-European populations. In conclusion, the identification of the ethnic group of families undergoing genetic counseling enables the geneticist and oncologist to make more specific choices, leading to simplify the clinical approach to genetic testing carried out on members of high-risk families. Futhermore, the high frequency of founder mutations, allowing to analyze a large number of cases, might provide accurate information regarding their penetrance.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 70 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations:: a combined analysis of 22 population based studies
    Antoniou, AC
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. JOURNAL OF MEDICAL GENETICS, 2005, 42 (07) : 602 - 603
  • [3] Frequency of BRCA1 mutation 5382insC in German breast cancer patients
    Backe, J
    Hofferbert, S
    Skawran, B
    Dörk, T
    Stuhrmann, M
    Karstens, JH
    Untch, M
    Meindl, A
    Burgemeister, R
    Chang-Claude, J
    Weber, BHF
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 72 (03) : 402 - 406
  • [4] Baudi F, 2001, Hum Mutat, V18, P163, DOI 10.1002/humu.1167
  • [5] A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques
    Bergman, A
    Flodin, A
    Engwall, Y
    Arkblad, EL
    Berg, K
    Einbeigi, Z
    Martinsson, T
    Wahlström, J
    Karlsson, P
    Nordling, M
    [J]. FAMILIAL CANCER, 2005, 4 (02) : 89 - 96
  • [6] The western Swedish BRCA1 founder mutation 3171ins5;: a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation
    Bergman, A
    Einbeigi, Z
    Olofsson, U
    Taib, Z
    Wallgren, A
    Karlsson, P
    Wahlström, J
    Martinsson, T
    Nordling, M
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2001, 9 (10) : 787 - 793
  • [7] Bergthorsson JT, 1998, HUM MUTAT, pS195
  • [8] Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
  • [9] Caligo MA, 1996, ONCOGENE, V13, P1483
  • [10] CIEMIKOVA S, 2006, NEOPLASMA, V53, P97